November 23, 2016 - By Vivian Park · 0 Comments
The stock of Lexicon Pharmaceuticals Incorporated (NASDAQ:LXRX) registered a decrease of 6.8% in short interest. LXRX’s total short interest was 13.64M shares in November as published by FINRA. Its down 6.8% from 14.64 million shares, reported previously. With 547,500 shares average volume, it will take short sellers 25 days to cover their LXRX’s short positions. The short interest to Lexicon Pharmaceuticals Incorporated’s float is 29.57%. About 302,771 shares traded hands. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has risen 15.33% since April 21, 2016 and is uptrending. It has outperformed by 10.00% the S&P500.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $1.68 billion. The Firm focuses on the development of treatments for human disease. It currently has negative earnings. The Firm is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211).
Out of 5 analysts covering Lexicon Pharmaceuticals (NASDAQ:LXRX), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Lexicon Pharmaceuticals has been the topic of 8 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating given on Monday, August 10 by JP Morgan. Gabelli downgraded Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) on Friday, September 18 to “Sell” rating. The rating was initiated by Citigroup on Tuesday, August 2 with “Buy”. The rating was upgraded by Gabelli on Monday, September 28 to “Hold”. The firm has “Outperform” rating given on Friday, August 5 by Wedbush. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Buy” rating given on Friday, October 7 by H.C. Wainwright.
Lexicon Pharmaceuticals, Inc. (Lexicon), incorporated on July 7, 1995, is a biopharmaceutical company. The Firm focuses on the development of treatments for human disease. The Firm is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211).
More important recent Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) news were published by: Prnewswire.com which released: “Lexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For …” on November 07, 2016, also Fool.com published article titled: “These Secret Ingredients Led Lexicon Pharmaceuticals, Inc. Up 109% in 2015”, Prnewswire.com published: “Lexicon Pharmaceuticals Announces Agreement To Buy Out Remaining Obligations …” on October 05, 2016. More interesting news about Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was released by: Prnewswire.com and their article: “FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid …” with publication date: September 14, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park